Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes

Diabetologia

Volumn 58, Issue 6, 2015, Pages 1183-1187

  Cefalu, William T ^a,b,c,d,e,f   Stenlöf, Kaj ^a,b,c,d,e,f   Leiter, Lawrence A ^a,b,c,d,e,f   Wilding, John P H ^a,b,c,d,e,f   Blonde, Lawrence ^a,b,c,d,e,f   Polidori, David ^a,b,c,d,e,f   Xie, John ^a,b,c,d,e,f   Sullivan, Daniel ^a,b,c,d,e,f   Usiskin, Keith ^a,b,c,d,e,f   Canovatchel, William ^a,b,c,d,e,f   Meininger, Gary ^a,b,c,d,e,f  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e OCHSNER MEDICAL CENTER   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Body weight; Canagliflozin; Sodium glucose co transporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; BLOOD; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; HUMAN; HYPERTENSION; MALE; METABOLISM; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLE; WEIGHT REDUCTION;

ADULT; AGED; BLOOD PRESSURE; BODY WEIGHT; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SYSTOLE; WEIGHT LOSS;

EID: 84939943275     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3547-2     Document Type: Article

References (14)

1. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379
2. American Medical Association House of Delegates (2013) Resolution 420 (A-13). Recognition of obesity as a disease. www.ama-assn.org/assets/meeting/2013a/a13-addendum-refcomm-d.pdf. Accessed 22 July 2013
3. Jensen MD, Ryan DH, Apovian CM et al (2014) 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129:S102–S138
4. Noria SF, Grantcharov T (2013) Biological effects of bariatric surgery on obesity-related comorbidities. Can J Surg 56:47–57
5. Wing RR, Lang W, Wadden TA et al (2011) Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 34:1481–1486
6. The Diabetes Prevention Program Research Group (2012) Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 35:731–737
7. Pi-Sunyer X, Blackburn G, Brancati FL et al (2007) Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 30:1374–1383
8. Wing RR, Bolin P, Brancati FL et al (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369:145–154
9. Stenlöf K, Cefalu WT, Kim K-A et al (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15:372–382
10. Lavalle-González FJ, Januszewicz A, Davidson J et al (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56:2582–2592
11. Wilding JP, Charpentier G, Hollander P et al (2013) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 67:1267–1282
12. Forst T, Guthrie R, Goldenberg R et al (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 16:467–477
13. Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E (2012) Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res 2012:672658
14. de las Cruces Souto-Gallardo M, Bacardi Gascon M, Jimenez Cruz A (2011) Effect of weight loss on metabolic control in people with type 2 diabetes mellitus: systematic review. Nutr Hosp 26:1242–1249